Abstract
Attempts to treat patients suffering from metastasizing or primary operable breast cancer in a risk adapted fashion have always been dependent on the detection and clinically relevant ranking of prognostic parameters. Despite a variety of assumed prognostic parameters and description of prognostic indices no generally accepted definition of low or high risk breast cancer has been established as yet. Nevertheless, attempts have been successful to accomplish risk adapted treatment strategies that resulted in a substantial reduction in treatment related morbidity. Thus, replacement of surgical ablation procedures by drugs manipulating hormonal feedback regulation has yielded less side effects. Furthermore, new antiestrogens and antigestagens are aiming at a reduction in the rate and degree of toxicity. In addition, chemotherapy of metastasizing disease as well as adjuvant systemic therapy is being investigated with consideration of the concept of a maximum in efficacy and a minimum in toxicity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
